Streetbeat News

Regulatory

ALK

HA

Hawaiian Holdings shares are trading higher after the company and Alaska Air agreed with the DOJ to extend the review period until August 16, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:49 am

ALK

HA

Hawaiian Holdings and Alaska Airlines have agreed with the DOJ to extend the review period for their agreement until August 16, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:48 am

ARCH

CHK

NEXT

The article highlights three oversold energy stocks with potential for short-term gains: Arch Resources Inc (ARCH), Nextdecade Corp (NEXT), and Chesapeake Energy Corp (CHK). These stocks have experienced significant price declines and have RSI values indicating they are oversold.

Portfolio Pulse from Avi Kapoor

August 14, 2024 | 11:43 am

F

Ford Motor Co. (NYSE:F) is recalling 37,371 vehicles, including the Mustang Mach-E EV SUV, due to potential front windshield wiper failures. The recall affects several 2023-2024 Ford Maverick vehicles, 2023 Ford Bronco Sport, and 2023 Mustang Mach-E SUVs. Ford will inspect and replace the wiper motors free of charge. No accidents or injuries have been reported related to this issue.

Portfolio Pulse from Anan Ashraf

August 14, 2024 | 11:42 am

VRCA

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) announced positive preliminary results from Part 2 of its Phase 2 clinical trial for VP-315, a potential first-in-class oncolytic peptide for treating basal cell carcinoma. The trial showed a 51% complete histological clearance of tumors and an 86% overall reduction in tumor size. No dose-limiting toxicities or serious adverse events were reported. The company plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:32 am

ALBT

Avalon GloboCare announced that its device has been approved for reimbursement by Medicare and is supported by several private insurance providers.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:30 am

OTLK

Outlook Therapeutics announced that the resubmission of its Biologics License Application (BLA) for ONS-5010 is on track for Q1 CY2025.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:13 am

TLSA

Tiziana Life Sciences announced that it has regained compliance with the Nasdaq listing minimum bid price requirement, ensuring its continued listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:12 am

VIRX

Viracta Therapeutics reported positive Phase 2 NAVAL-1 trial results for its treatment of relapsed or refractory Epstein-Barr Virus-Positive Peripheral T-cell Lymphoma. The company also received productive feedback from the FDA, providing clarity on the regulatory path for Nana-val. Viracta plans to begin a randomized controlled trial in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 11:09 am

TSLA

The National Highway Traffic Safety Administration (NHTSA) has closed a 3-year investigation into nearly 75,000 Tesla vehicles over concerns of front suspension failure. The investigation, which began in November 2020, found no instances of part failure resulting in loss of vehicle control. However, NHTSA recommended that Tesla expand its 2017 consumer satisfaction bulletin to cover all affected vehicles.

Portfolio Pulse from Anan Ashraf

August 14, 2024 | 10:59 am